UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 2126-15
Program Prior Authorization/Medical Necessity
Medication Siliq (brodalumab)*
*Siliq is excluded from coverage for the majority of our benefits
P&T Approval Date 5/2017, 2/2018, 2/2019, 9/2019, 5/2020, 5/2021, 6/2021, 12/2021,
5/2022, 11/2022, 1/2023, 4/2023, 7/2023, 10/2024, 4/2025
Effective Date 6/1/2025
1. Background:
Siliq (brodalumab) is a human interleukin-17 receptor A (IL-17RA) antagonist indicated
for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates
for systemic therapy or phototherapy and have failed to respond or have lost response to
other systemic therapies.
2. Coverage Criteriaa:
A. Plaque Psoriasis
a. Siliq will be approved based on the following criteria:
(1) Submission of medical records (e.g., chart notes, laboratory values, prescription
claims history) documenting all of the following:
(a) Diagnosis of chronic moderate to severe plaque psoriasis
-AND-
(b) One of the following:
i. All of the following:
1. Greater than or equal to 3% body surface area involvement,
palmoplantar, facial, genital involvement, or severe scalp psoriasis
-AND-
2. History of failure to one of the following topical therapies, unless
contraindicated or clinically significant adverse effects are
experienced (document drug, date, and duration of trial):
 Corticosteroids (e.g., betamethasone, clobetasol, desonide)
 Vitamin D analogs (e.g., calcitriol, calcipotriene)
 Tazarotene
 Calcineurin inhibitors (e.g., tacrolimus, pimecrolimus)
 Anthralin
© 2025 UnitedHealthcare Services Inc.
1
 Coal tar
-AND-
3. History of failure to a 3 month trial of methotrexate at maximally
indicated dose, unless contraindicated or clinically significant adverse
effects are experienced (document drug, date, and duration of trial)b^
-OR-
ii. Patient has been previously treated with a targeted immunomodulator
FDA-approved for the treatment of plaque psoriasis as documented by
claims history or submission of medical records (Document drug, date,
and duration of therapy) [e.g., Cimzia (certolizumab), adalimumab, Otezla
(apremilast), Skyrizi (risankizumab), ustekinumab, Tremfya
(guselkumab), Enbrel (etanercept)].
-AND-
(c) History of failure, contraindication, or intolerance to three of the following
preferred products (document drug, date, and duration of trial):^
i. One of the preferred adalimumab productsc
ii. Cimzia (certolizumab)
iii. Cosentyx (secukinumab)
iv. Enbrel (etanercept)
v. Skyrizi (risankizumab)
vi. Sotyktu (deucravacitinib)
vii. One of the preferred ustekinumab productsc
viii. Tremfya (guselkumab)
-AND-
(d) Patient is not receiving Siliq in combination with another targeted
immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi
(golimumab), Orencia (abatacept), adalimumab, ustekinumab, Skyrizi
(risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab), Taltz
(ixekizumab), Ilumya (tildrakizumab), Xeljanz (tofacitinib), Olumiant
(baricitinib), Rinvoq (upadacitinib), Otezla (apremilast)]
-AND-
(e) Prescribed by or in consultation with a dermatologist
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
b For Connecticut, Kentucky and Mississippi business only a 30-day trial will be required.
© 2025 UnitedHealthcare Services Inc.
2
c For a list of preferred products please reference drug coverage tools.
^Tried/failed alternative(s) are supported by FDA labeling.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-10)
and/or claim logic. Use of automated approval and re-approval processes varies by program
and/or therapeutic class.
• *Siliq is excluded from coverage for the majority of our benefits
• Supply limits may be in place.
4. References:
1. Siliq [package insert]. Bridgewater, NJ: Bausch Health US, LLC; April 2020.
2. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis
and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the
treatment of psoriasis with biologics. J Am Acad Dermatol 2008; 58(5):826-50.
3. Gottlieb A, Korman NJ, Gordon KB, et al. Guidelines of care for the management of
psoriasis and psoriatic arthritis. Psoriatic arthritis: Overview and guidelines of care for
treatment with an emphasis on the biologics. J Am Acad Dermatol 2008;58(5):851-64.
4. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis
and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of
psoriasis with topical therapies. J Am Acad Dermatol 2009;60(4):643-59.
5. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis
and psoriatic arthritis. Guidelines of care for the treatment of psoriasis with phototherapy and
photochemotherapy. J Am Acad Dermatol 2010;62(1):114-35.
6. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis
and psoriatic arthritis. Guidelines of care for the management and treatment of psoriasis with
traditional systemic agents. J Am Acad Dermatol 2009;61(3):451-85.
7. Menter A, Korman NJ, Elmets CA,Feldman SR, Gelfand JM, Gordon KB, Guidelines of care
for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the
treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based
conclusions. J Am Acad Dermatol. 2011 Jul;65(1):137-74.
8. Nast A, et al; European S3-Guidelines on the systemic treatment of psoriasis vulgaris –
update 2015 – short version – EFF in cooperation with EADV and IPC, J Eur Acad Derm
Venereol 2015;29:2277-94.
9. Menter A, Strober BE, Kaplan DH et al. Joint AAD-NPF guidelines of care for the
management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019:80:1029-
72.
Program Prior Authorization/Medical Necessity-Siliq (brodalumab)
Change Control
Date Change
5/2017 New Program.
2/2018 Updated criteria, adding Tremfya as an additional preferred agent for
plaque psoriasis.
2/2019 Annual review. Added manufacturer assistance program information.
Updated background. Addition of Cimzia as preferred agent.
© 2025 UnitedHealthcare Services Inc.
3
9/2019 Updated criteria adding Skyrizi as preferred medication. Added
coverage exclusion statement. Updated references.
5/2020 Updated formatting without change to clinical intent.
5/2021 Annual review. Removed drug documentation where only one drug is
required. Updated references.
6/2021 Added coverage criteria for patients previously treated with a biologic
DMARD.
12/2021 Updated the following with no change to clinical intent: updated
conventional DMARD bypass language for psoriasis, removed
“biologic” from required preferred product criteria language and
updated CT/KY footnote.
5/2022 Updated with Tried/failed alternative(s) are supported by FDA labeling
footnote. Added Mississippi to state mandate.
11/2022 Added Enbrel as a preferred product step option. Added Enbrel as an
example where appropriate.
1/2023 Updated step therapy requirements to Humira or Amjevita. Updated
listed examples from Humira to adalimumab.
4/2023 Updated step therapy requirement from Humira or Amjevita to one of
the preferred adalimumab products and added the footnote “For a list of
preferred adalimumab products please reference drug coverage tools.”
7/2023 Updated not receiving in combination language to targeted
immunomodulator and updated examples.
10/2024 Updated step requirement noting Adalimumab-adaz (unbranded
Hyrimoz), Amjevita for Nuvaila, and Humira as preferred adalimumab
products with no change to clinical intent. Removed preferred
adalimumab footnote. Added Sotyktu as step therapy agent. Moved
Cosentyx to preferred step agent and changed step to three agents.
Updated state mandate footnote.
4/2025 Removed examples for adalimumab in step therapy. Changed Stelara
step therapy to “One of the preferred ustekinumab productsc”. Changed
Stelara example to Ustekinumab. Added the footnote “For a list of
preferred products please reference drug coverage tools.”
© 2025 UnitedHealthcare Services Inc.
4